Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

1.

Single-dose infliximab in hepatitis C genotype 1 treatment-naive patients with high serum tumour necrosis factor-alpha does not influence the efficacy of pegylated interferon alpha-2b/ribavirin therapy.

Cooper C, Shafran S, Greenbloom S, Enns R, Farley J, Hilzenrat N, Williams K, Elkashab M, Abadir N, Neuman M.

Can J Gastroenterol Hepatol. 2014 Jan;28(1):35-40. Epub 2013 Nov 8.

PMID:
24212915
[PubMed - in process]
Free PMC Article
2.

Early and sustained virological response in non-responders with chronic hepatitis C: a randomized open-label study of pegylated interferon-alpha-2a versus pegylated interferon-alpha-2b.

Scotto G, Fazio V, Fornabaio C, Tartaglia A, Di Tullio R, Saracino A, Angarano G.

Drugs. 2008;68(6):791-801.

PMID:
18416586
[PubMed - indexed for MEDLINE]
3.

Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.

Escudero A, Rodríguez F, Serra MA, Del Olmo JA, Montes F, Rodrigo JM.

J Gastroenterol Hepatol. 2008 Jun;23(6):861-6. doi: 10.1111/j.1440-1746.2008.05397.x. Epub 2008 Apr 19.

PMID:
18422960
[PubMed - indexed for MEDLINE]
4.

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.

Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J.

Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. Review.

PMID:
15461877
[PubMed - indexed for MEDLINE]
Free Article
5.

Comparative study of the efficacy of an induction dose of interferon-alpha2b with ribavirin compared with standard combined treatment in naive patients with chronic hepatitis C.

Pérez R, Jiménez M, Crespo J, Diago M, Enríquez J, Vaquero P, Solá R, Olcoz JL, Romero M, Salmerón J, Blanco MI, Oña M, Melón S, Rodrigo L; Grupo Inter-Hospitalario Español.

J Viral Hepat. 2003 Nov;10(6):437-45.

PMID:
14633177
[PubMed - indexed for MEDLINE]
6.

Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.

Napoli N, Giannelli G, Parisi CV, Antonaci A, Maddalena G, Antonaci S.

New Microbiol. 2005 Jan;28(1):13-21.

PMID:
15782622
[PubMed - indexed for MEDLINE]
7.

Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.

El-Zayadi AR, Attia M, Barakat EM, Badran HM, Hamdy H, El-Tawil A, El-Nakeeb A, Selim O, Saied A.

Am J Gastroenterol. 2005 Nov;100(11):2447-52.

PMID:
16279899
[PubMed - indexed for MEDLINE]
8.

Daily interferon induction regimen using different manufactured interferons (alpha-2A or alpha-2B) in combination with ribavirin for treatment of chronic hepatitis C: a prospective randomized study.

Braga EL, Lyra AC, Nascimento L, Netto E, Kalabrik L, Lyra LG.

Arq Gastroenterol. 2006 Oct-Dec;43(4):275-9.

PMID:
17406754
[PubMed - indexed for MEDLINE]
Free Article
9.

Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.

Yamada G, Iino S, Okuno T, Omata M, Kiyosawa K, Kumada H, Hayashi N, Sakai T.

Clin Drug Investig. 2008;28(1):9-16. Erratum in: Clin Drug Investig. 2008;28(4):210.

PMID:
18081356
[PubMed - indexed for MEDLINE]
10.

Pegylated interferon alpha-2b, ribavirin and amantadine for chronic hepatitis C.

Younossi ZM, McCullough AC, Barnes DS, Post A, Ong JP, O'Shea R, Martin LM, Bringman D, Farmer D, Levinthal G, Mullen KD, Carey WD, Tavill AS, Ferguson R, Gramlich T.

Dig Dis Sci. 2005 May;50(5):970-5.

PMID:
15906777
[PubMed - indexed for MEDLINE]
11.

Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial.

Liu CH, Liu CJ, Lin CL, Liang CC, Hsu SJ, Yang SS, Hsu CS, Tseng TC, Wang CC, Lai MY, Chen JH, Chen PJ, Chen DS, Kao JH.

Clin Infect Dis. 2008 Nov 15;47(10):1260-9. doi: 10.1086/592579.

PMID:
18834319
[PubMed - indexed for MEDLINE]
Free Article
12.

Pegylated interferon-alpha2b plus ribavirin: an efficacious and well-tolerated treatment regimen for patients with hepatitis C virus related histologically proven cirrhosis.

Roffi L, Colloredo G, Pioltelli P, Bellati G, Pozzpi M, Parravicini P, Bellia V, Del Poggio P, Fornaciari G, Ceriani R, Ramella G, Corradi C, Rossini A, Bruno S; Gruppo Epatologico Lombardo.

Antivir Ther. 2008;13(5):663-73.

PMID:
18771050
[PubMed - indexed for MEDLINE]
13.

The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response.

Napoli N, Giannelli G, Antonaci A, Antonaci S.

J Viral Hepat. 2008 Apr;15(4):300-4. doi: 10.1111/j.1365-2893.2007.00944.x.

PMID:
18307592
[PubMed - indexed for MEDLINE]
14.

Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.

Sulkowski M, Pol S, Mallolas J, Fainboim H, Cooper C, Slim J, Rivero A, Mak C, Thompson S, Howe AY, Wenning L, Sklar P, Wahl J, Greaves W; P05411 study investigators.

Lancet Infect Dis. 2013 Jul;13(7):597-605. doi: 10.1016/S1473-3099(13)70149-X. Epub 2013 Jun 12.

PMID:
23768747
[PubMed - indexed for MEDLINE]
15.

Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.

Furusyo N, Ogawa E, Nakamuta M, Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, Tanabe Y, Kotoh K, Shimoda S, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group.

J Hepatol. 2013 Aug;59(2):205-12. doi: 10.1016/j.jhep.2013.03.020. Epub 2013 Mar 28.

PMID:
23542346
[PubMed - indexed for MEDLINE]
16.

A randomized trial of 48 versus 24 weeks of combination pegylated interferon and ribavirin therapy in genotype 6 chronic hepatitis C.

Thu Thuy PT, Bunchorntavakul C, Tan Dat H, Rajender Reddy K.

J Hepatol. 2012 May;56(5):1012-8. doi: 10.1016/j.jhep.2011.12.020. Epub 2012 Jan 17.

PMID:
22266603
[PubMed - indexed for MEDLINE]
17.

Treatment for Hepatitis C Virus Infection in Adults [Internet].

Chou R, Hartung D, Rahman B, Wasson N, Cottrell E, Fu R.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Nov.

PMID:
23304740
[PubMed]
Books & Documents
18.

Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance.

Khattab M, Emad M, Abdelaleem A, Eslam M, Atef R, Shaker Y, Hamdy L.

Liver Int. 2010 Mar;30(3):447-54. doi: 10.1111/j.1478-3231.2009.02171.x. Epub 2009 Nov 16.

PMID:
19919569
[PubMed - indexed for MEDLINE]
19.

Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients.

Laguno M, Cifuentes C, Murillas J, Veloso S, Larrousse M, Payeras A, Bonet L, Vidal F, Milinkovic A, Bassa A, Villalonga C, Pérez I, Tural C, Martínez-Rebollar M, Calvo M, Blanco JL, Martínez E, Sánchez-Tapias JM, Gatell JM, Mallolas J.

Hepatology. 2009 Jan;49(1):22-31. doi: 10.1002/hep.22598. Erratum in: Hepatology. 2009 Mar;49(3):1058.

PMID:
19085908
[PubMed - indexed for MEDLINE]
20.

Sustained viral response to pegylated interferon alpha-2b and ribavirin in chronic hepatitis C refractory to prior treatment.

Mathew A, Peiffer LP, Rhoades K, McGarrity T.

Dig Dis Sci. 2006 Nov;51(11):1956-61. Epub 2006 Sep 27.

PMID:
17004124
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk